p53 Antibody / TP53 N-Terminal Region

NSJ Bioreagents
Product Code: NSJ-V3647IHC
Product Group: Primary Antibodies
Supplier: NSJ Bioreagents
CodeSizePrice
NSJ-V3647IHC-7ML7 ml£534.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: Mouse IgG1 kappa
Antibody Clonality: Recombinant Antibody
Antibody Clone: rBP53-12
Regulatory Status: RUO
Target Species: Human
Application: Immunohistochemistry- Paraffin Embedded (IHC-P)
Storage:
Store the recombinant TP53 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Images

1 / 2
IHC testing of FFPE human colon carcinoma with recombinant TP53 antibody. Required HIER: boil tissue sections in pH6, 10mM citrate buffer, for 10-20 min followed by cooling at RT for 20 min.~
2 / 2
SDS-PAGE analysis of purified, BSA-free recom

IHC testing of FFPE human colon carcinoma with recombinant TP53 antibody. Required HIER: boil tissue sections in pH6, 10mM citrate buffer, for 10-20 min followed by cooling at RT for 20 min.~
SDS-PAGE analysis of purified, BSA-free recom

Documents

Further Information

Application Details:
The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Application Note:
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the recombinant TP53 antibody to be titered up or down for optimal performance.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Description:
This MAb reacts with an N-terminal epitope (aa 16-25) of both wild type and mutated p53. Mutation and/or allelic loss of p53 is one of the causes of a variety of mesenchymal and epithelial tumors. If it occurs in the germ line, such tumors run in families. In most transformed and tumor cells the concentration of p53 is increased 5 1000 fold over the minute concentrations (1000 molecules cell) in normal cells, principally due to the increased half-life (4 h) compared to that of the wild-type (20 min). p53 Localizes in the nucleus, but is detectable at the plasma membrane during mitosis and when certain mutations modulate cytoplasmic/nuclear distribution. Mutations arise with an average frequency of 70% but incidence varies from zero in carcinoid lung tumors to 97% in primary melanomas. High concentrations of p53 protein are transiently expressed in human epidermis and superficial dermal fibroblasts following mild ultraviolet irradiation. Positive nuclear staining with p53 antibody has been reported to be a negative prognostic factor in breast carcinoma, lung carcinoma, colorectal, and urothelial carcinoma. Anti-p53 positivity has also been used to differentiate uterine serous carcinoma from endometrioid carcinoma as well as to detect intratubular germ cell neoplasia.
Format:
Purified
Formulation:
Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*
Gene ID #:
7157
Immunogen:
Recombinant human wild-type p53 protein was used as the immunogen for this recombinant TP53 antibody. The epitope has been mapped to within amino acids 16-25.
Limitation:
This recombinant TP53 antibody is available for research use only.
Localization:
Nuclear
Purity:
Protein G affinity chromatography